Connect with us

Technology

MiniMed launches Instinct sensors in Europe giving people with diabetes more sensor choice with the same proven outcomes

Published

on

MiniMed automated insulin delivery and smart MDI systems can now be paired with Instinct and Instinct Go, made by Abbott, the smallest, longest-wear sensors in the company’s portfolio

NORTHRIDGE, Calif., June 23, 2026 /PRNewswire/ — MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today announced the commercial launch in Europe of both the MiniMed™ 780G system integrated with the Instinct sensor and the MiniMed Go™ system integrated with the Instinct Go sensor. The Instinct and Instinct Go sensors, made by Abbott, will be rolled out gradually across Europe starting this month, expanding MiniMed’s sensor portfolio in the region. 

“People with diabetes should not have to choose between flexibility and performance when managing their diabetes — and with MiniMed, they don’t have to,” said Que Dallara, CEO, MiniMed. “Expanding our sensor portfolio across Europe with Instinct and Instinct Go means more people can access the proven outcomes, intelligent insights, and seamless automation MiniMed is known for. This is about meeting people where they are and building technology that fits their life — not the other way around. That’s what drives us every day.”

For people with type 1 diabetes, accurately counting carbs and remembering to take insulin up to 15 minutes before meals can be challenging, often leading to post-meal blood glucose spikes when doses are delayed, missed, or underestimated.

The MiniMed™ 780G system is the only system with Meal Detection™ technology* designed to reduce post-meal blood glucose spikes when users occasionally forget to bolus or underestimate carbs. Paired with the 15-day Instinct sensor—the world’s smallest, thinnest, and most discreet sensor with demonstrated strong glucose accuracy1,2—the MiniMed™ 780G system offers greater choice and flexibility while maintaining proven clinical performance. Recent data from a new randomized crossover study, published in Diabetes Technology & Therapeutics, demonstrated glycemic outcomes were virtually identical when using the MiniMed™ 780G system with either the Simplera Sync™ sensor or Instinct sensor. These results were reinforced by a real-world analysis of over 20,000 U.S. users of the MiniMed 780G system, validating the algorithm’s central role in driving results.6,7

Clinical and real-world evidence suggest that the MiniMed™ 780G system can help people with type 1 diabetes achieve consistent glycemic control that substantially exceeds ADA and international consensus guidelines of 70% Time in Range (TIR), with many users achieving 80% TIR3,4  ∞ when using optimal settings. A separate real-world study of 8,019 U.S. MiniMed™ 780G system users (aged 7 years or older) demonstrated that the system delivered 91% overnight Time in Range5 **^ ∞ which means fewer beeps, fewer alarms and a restful sleep.

For people using multiple daily injections (MDI), diabetes management remains fragmented across disconnected tools, creating constant “mental math” in daily life. The MiniMed Go™ system integrated with the Instinct Go sensor brings it all together in one place. It is the first solution to combine dose tracking with the InPen™ smart insulin pen and real-time CGM data, addressing the therapy adherence gap for MDI users by providing real-time alerts and actionable insights on a single mobile app when doses are missed or blood glucose spikes – helping MDI users stay on top of their diabetes with less effort.

“People with diabetes have different preferences, lifestyles, and needs, which is why choice matters,” said Professor Amir Tirosh of Sheba Medical Center and Tel-Aviv University. “The integration of the Instinct sensor with the MiniMed™ 780G and MiniMed Go™ systems allows more people to access advanced diabetes technology in a way that works for them, while still benefiting from the proven algorithm and clinical outcomes that have made these systems so impactful.”

The Instinct and Instinct Go sensors begin rolling out across European markets this month following CE mark approval earlier this year for integration with the two systems.

Frequently Asked Questions
Q: What is the MiniMed™ 780G system?
A: It’s MiniMed’s most advanced automated insulin delivery system that automatically adjusts insulin every five minutes based on real-time glucose readings, helping reduce highs and lows and making diabetes management easier and less time-consuming.§

Q: What is the MiniMed Go™ system?
A: The MiniMed Go™ system is a smart diabetes management solution that connects the InPen™ smart insulin pen with either the Simplera™ sensor or Instinct Go sensor, made by Abbott, through the single MiniMed Go™ app. It provides real-time glucose data, dose calculations, missed dose alerts, and actionable guidance, making MDI therapy easier and more connected.

Q: What makes the Instinct sensor different?
A: The Instinct sensor, made by Abbott, is easy to use and comfortable to wear8 for up to 15 days. It’s the world’s smallest1,2, thinnest1 and most discreet2 sensor and is designed to work exclusively with MiniMed smart dosing systems.

*Taking a bolus 15 – 20 minutes before a meal helps to keep blood sugar levels under control after eating.
** Overnight period: 12:00 AM- 6:00 AM [24:00 h–06:00 h]. CareLink™ data including CGM metrics, alarms/alerts, and insulin delivery were evaluated in 8019 US MiniMed™ 780G system users (aged ≥7 years, as of 6 November 2023) who transitioned from the MiniMed™ 770G system and had ≥14 nights of CGM data on both systems. CareLink™ data were analysed between 26 February 2023, and 21 October 2023, for MiniMed™ 770G users, and between 8 August 2023, and 6 November 2023, for MiniMed™ 780G users.
§ Refers to SmartGuard™ feature. Individual results may vary
^ Due to inherent analysis limitations, caution is advised when attempting to extrapolate these results to new patients. There could be significant differences.
∞ Reached using optimal settings, Optimal settings are glucose target at 100 mg/dL (5.5 mmol/L) and Active Insulin Time (AIT) at 2 hours and used >95% of the time. SmartGuard™ feature settings for each single patient must be defined by HCPs based on individual targets and specific needs

The sensor shape and appearance, Abbott, and “a” logo are marks and/or designs of the Abbott group of companies in various territories and used under license. Sensor image © 2026 Abbott. ™* Third–party brands are trademarks of their respective owners.

Among patient-applied sensors.Data on file. Abbott Diabetes Care, Inc.Thrasher JR, Arrieta A, Niu F, Cameron KR, Cordero TL, Shin J, Rhinehart AS, Vigersky RA. Early Real-World Performance of the MiniMed™ 780G Advanced Hybrid Closed-Loop System and Recommended Settings Use in the United States. Diabetes Technol Ther. 2024 Mar;26(S3):24-31. doi: 10.1089/dia.2023.0453. PMID: 38377317Choudhary P, Arrieta A, van den Heuvel T, Castañeda J, Smaniotto V, Cohen O. Celebrating the Data from 100,000 Real-World Users of the MiniMed™ 780G System in Europe, Middle East, and Africa Collected Over 3 Years: From Data to Clinical Evidence. Diabetes Technol Ther. 2024 Mar;26(S3):32-37. doi: 10.1089/dia.2023.0433. PMID: 38377326; PMCID: PMC10890936.McVean, et al. . Diabetes Obes Metab. 2026;28(3):2456-2460Laron-Hirsch, M., et al. Glycemic concordance of Simplera Sync™ and Instinct sensors in MiniMed™ 780G system users: A randomized crossover feasibility study. Diabetes Technology and Therapeutics. DOI:10.1177/15209156261449884Data on file.Alva, Shridhara, Ronald Brazg, Kristin Castorino, Mark Kipnes, David R. Liljenquist, and Hanqing Liu. “Accuracy of the Third Generation of a 14-Day Continuous Glucose Monitoring System.” Diabetes Therapy 14, no. 4 (2023): 767-776. https://doi.org/10.1007/s13300-023-01385-6.

About MiniMed
MiniMed is a global leader in insulin delivery, constantly advancing therapies that support people with diabetes in more than 80 countries. Our full-stack, integrated ecosystem, including our insulin delivery systems, CGMs, algorithms, and easy-to-use app experience, is designed to work seamlessly together, supported by white-glove, wrap-around service. For over 40 years, we’ve pioneered therapies people can rely on by anticipating needs, reducing burden, and helping make life with diabetes easier. Our mission is to make every day a better day for people with diabetes.

Any forward-looking statements are subject to risks and uncertainties such as those described in MiniMed’s periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

View original content to download multimedia:https://www.prnewswire.com/news-releases/minimed-launches-instinct-sensors-in-europe-giving-people-with-diabetes-more-sensor-choice-with-the-same-proven-outcomes-302806652.html

SOURCE MiniMed

Continue Reading

Technology

University of Phoenix Highlights Student Success Stories from President’s and Dean’s List Honorees

Published

on

By

Student reflections from President’s and Dean’s List honorees highlight flexibility, career-focused learning and perseverance while balancing work, family and education

PHOENIX, Sept. 9, 2026 /PRNewswire/ — University of Phoenix is spotlighting the experiences of students recognized on its July 2026 President’s and Dean’s Lists, sharing stories that illustrate the dedication, persistence and personal goals behind their academic achievement. As an extension of the July 2026 recognition, the University hosted a giveaway for President’s and Dean’s List honorees and invited eligible students to join the University of Phoenix subreddit and share what had been most valuable about their educational journeys. Responses submitted as part of the giveaway highlighted themes including flexibility, career-focused learning, and pursuing educational goals while balancing work, family and other responsibilities.

Celebrating Student Achievement Across University Programs

In July, the University recognized 32,416 students for academic achievement through its semi-annual President’s and Dean’s Lists. The President’s List honored 9,496 students who earned a 4.0 grade point average (GPA), while 22,920 students were named to the Dean’s Lists for achieving high academic standing in their programs of study.

“Behind every President’s and Dean’s List recognition is a unique story of commitment, perseverance and purpose,” said John Woods, PhD, provost and chief academic officer at University of Phoenix. “The student reflections shared through this initiative highlight the determination our learners bring to their educational journeys and the many ways they balance academic goals alongside career, family and personal responsibilities. We are proud to celebrate not only their academic achievement, but also the experiences that helped shape their success.”

Key Themes Shared by President’s and Dean’s List Students

The giveaway generated 787 eligible student submissions on the University of Phoenix subreddit, with 30 participants selected to receive University of Phoenix swag boxes.

In reviewing the submissions, the University identified several recurring themes, including:

Flexibility to balance education with work and family responsibilitiesCoursework that aligned directly to career goalsEducational milestones such as becoming the first in a family to earn a college degreeContinued learning through advanced degree programs

Students Share Their Educational Journeys

Derell Vanstory, who recently completed a Bachelor of Science in Business and earned Dean’s List recognition, reflected on balancing school, work and family responsibilities while pursuing his degree. This fall, he plans to pursue dual master’s degrees, an MBA and Master of Health Administration, as he works toward a career in healthcare leadership.

“The most valuable part of my journey at the University of Phoenix has been learning how to stay disciplined and resilient,” said Vanstory. “Balancing school, work, and family responsibilities taught me that success isn’t about having an easy path, it’s about continuing to move forward even when things get difficult.”

Reenae Flores, who is pursuing a Bachelor of Science in Business with a concentration in Human Resource Management, described Dean’s List recognition as a meaningful milestone in her educational journey.

“This recognition represents so much more than a GPA,” said Flores. “It represents late nights after work, balancing family life, pushing through challenges, and refusing to give up on a dream that once felt out of reach.”

Flores shared that the flexibility of her educational experience allowed her to continue growing professionally while remaining present for her family.

Alisha Saffold, who recently completed a Bachelor of Science in Health Management, graduated summa cum laude with a 4.0 GPA, and is continuing her education as a Master of Public Health student, highlighted the value of applying classroom learning directly to her professional goals.

“The most valuable part of my University of Phoenix experience has been learning how to apply what I studied directly to my career and my passion for serving others,” said Saffold. “Every course challenged me to think like a healthcare leader and strengthened my commitment to improving access to preventive care, advancing health equity, and making a difference in underserved communities.”

Academic Achievement Among Working Adult Learners

The experiences shared by President’s and Dean’s List honorees reflect those of many University of Phoenix students who pursue education while balancing work, family and other responsibilities. According to University data, 75.4% of students are employed. In the Encoura + Ruffalo Noel Levitz Priorities Survey for Online Learners, 63% of University student respondents indicated they have caregiving responsibilities, while 91% expressed satisfaction that their chosen program aligns with their career path and that the course format fits into their busy lives.

To support students managing these competing demands, University of Phoenix offers resources including flexible course scheduling, on-demand support and access to its Life Resource Center.

About University of Phoenix

University of Phoenix is Built for Real Life. 50 Years Strong. The University innovates to help working adults enhance their careers and develop skills in a rapidly changing world through flexible online learning, relevant courses, academic AI pillars, and skills-mapped curriculum for associate, bachelor’s and master’s degree programs. Active students and alumni have access to Career Services for Life® resources including career guidance and tools. For more information, visit phoenix.edu.

View original content to download multimedia:https://www.prnewswire.com/news-releases/university-of-phoenix-highlights-student-success-stories-from-presidents-and-deans-list-honorees-302874381.html

SOURCE University of Phoenix

Continue Reading

Technology

iFlex Stretch Studios Adds Kinotek® 3D Movement Technology to Every Experience

Published

on

By

The assisted stretching franchise combines markerless, AI-driven movement analysis with certified stretch therapist expertise to deliver more personalized programming and enhanced member experiences.

NEWPORT BEACH, Calif., Sept. 9, 2026 /PRNewswire/ — iFlex Stretch Studios, the assisted stretching and mobility brand under Sequel Brands, today announced the addition of Kinotek®’s 3D movement assessment technology across its studio network. The integration provides iFlex stretch therapists with a precise, visual understanding of each client’s mobility, potential asymmetries, and movement patterns to further personalize their stretching experience.

Before a therapist begins a session, Kinotek’s markerless 3D movement assessment captures a client’s body in motion – no markers, sensors, or wearables required. In seconds, the technology analyzes range of motion, symmetry, and movement quality to provide deeper insights into each client’s mobility needs.

Each initial assessment helps establish a personalized stretching plan, with movement data informing AI-supported programming that therapists use to customize sessions, recommend at-home mobility work, and suggest recovery and mobility products aligned with individual goals.

“Assisted stretching has always come down to what a good stretch therapist can see and feel,” said Verdine Baker, Founder of iFlex Stretch Studios. “Kinotek gives our therapists a second set of eyes. It shows them things the human eye may miss and gives clients a clear way to see their progress session over session.”

The rollout follows a period of steady growth for iFlex, which has expanded across Arizona, Texas, Florida, California, Georgia, New Mexico, and Virginia under Sequel Brands while continuing to add franchise territories nationwide. Adding Kinotek across the network builds on the brand’s commitment to a more technology-driven studio experience, following the introduction of AI-supported client communication tools earlier this year.

“Movement health is one of the clearest predictors of how well and how independently people live as they age, and until recently there was no fast, practical way to measure it,” said Dr. Marty Miller, Chief Movement Officer at Kinotek. “iFlex is putting an objective measurement in front of every client and pairing it with therapists trained to act on it. Data plus skilled hands is what actually changes outcomes.”

For clients, Kinotek establishes a baseline at the first visit and enables progress tracking over time through easy-to-understand scored movement reports. The technology transforms mobility improvements into measurable insights, helping clients visualize progress beyond simply feeling better.

The technology is now available at participating iFlex locations, with additional studios rolling out Kinotek in the coming months.

To learn more about iFlex Stretch Studios, book a session, or inquire about franchise ownership, visit www.iflexstretchstudios.com or follow @iFlexStretchStudios on social media.

About iFlex Stretch Studios

iFlex Stretch Studios is a Sequel Brands company and a premier assisted stretching franchise offering personalized, therapist-led sessions designed to improve mobility, flexibility, and overall wellness. Founded in 2022 and acquired by Sequel Brands in 2025, iFlex has expanded from its first Arizona studio to locations across Texas, Florida, California, Georgia, New Mexico, and Virginia under the leadership of CEO Verdine Baker. Each guest begins with a personalized flexibility assessment, with ongoing progress tracking to support customized programming. iFlex is actively expanding franchise opportunities nationwide.

About Kinotek

Kinotek is a movement health company serving fitness, wellness, and medical professionals. Its markerless 3D platform measures a client’s movement in seconds, giving trainers, therapists, and clinicians an objective read on movement health – a leading indicator of longevity – and a way to track progress over time. For more information go to www.kinotek.com.

Media Contact:
Sequel Brands Communications
communications@sequelbrands.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/iflex-stretch-studios-adds-kinotek-3d-movement-technology-to-every-experience-302874396.html

SOURCE iFlex Stretch Studios

Continue Reading

Technology

BioEdge Research Labs Advances Transparency in Research Compound Documentation

Published

on

By

US-based research peptide supplier expands access to batch-level analytical documentation for its research-use-only materials, so researchers can verify identity and purity records for the lot they receive. All products are sold for laboratory research use only.

MIAMI, Sept. 9, 2026 /PRNewswire/ — BioEdge Research Labs, a United States-based supplier of research peptides and reference materials, today announced an initiative to advance transparency in how its research materials are documented. The initiative expands researcher access to batch-level analytical records for the company’s research-use-only materials.

Transparency has become a distinguishing factor in the research materials market. Because documentation practices vary from supplier to supplier, laboratory and research customers increasingly look for records they can review and confirm, rather than relying on a supplier’s summary alone. BioEdge’s initiative centers on making batch-level analytical documentation accessible for the material a researcher actually receives.

Accessible Certificates of Analysis

Each lot supplied by BioEdge is paired with its own Certificate of Analysis (COA), and batch-specific COAs are made available on the company’s product pages. Rather than a single certificate carried across multiple production runs, each vial carries a lot number that corresponds to the documentation for that batch, so the record can be matched to the material in hand.

Independent Analysis Behind the Record

The documentation reflects analysis performed by an independent third-party laboratory, covering identity by mass spectrometry (MS), purity by high-performance liquid chromatography (HPLC), and contaminant screening. Because the underlying analysis is conducted by a separate laboratory, the record reflects more than a supplier’s own description of the material.

Records a Researcher Can Match

The emphasis on batch-level records is intended to let a researcher confirm that a document corresponds to the specific lot received. Matching the lot number on the vial to its Certificate of Analysis is a straightforward check, and one that BioEdge’s documentation practices are designed to support across the product line.

Research Use Only

All materials supplied by BioEdge Research Labs are sold strictly for laboratory research and in vitro use by qualified researchers and scientific professionals. They are not drugs, supplements, or medical products.

About BioEdge Research Labs

BioEdge Research Labs is a United States-based supplier of research peptides and reference materials serving laboratory and research customers. The company sources from reputable U.S.-based facilities and supports its research-grade materials with independent third-party analytical testing and batch-specific Certificates of Analysis. Learn more at https://bioedgeresearchlabs.com

Media Contact

BioEdge Research Labs
2751 Biscayne Harbor Drive, Suite 620
Miami, FL 33137
(305) 757-0163
admin@thebioedgeresearchlabs.com

All products sold by BioEdge Research Labs are intended strictly for laboratory research and in vitro use by qualified researchers and scientific professionals. These products are not intended to diagnose, treat, cure, or prevent any disease, are not intended to affect the structure or any function of the body, and are not intended for human or veterinary use, consumption, or self-administration. They have not been evaluated or approved by the U.S. Food and Drug Administration for diagnostic, therapeutic, or preventative purposes. BioEdge Research Labs is a chemical supplier and is not a compounding pharmacy or outsourcing facility as defined under Sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act. BioEdge Research Labs makes no therapeutic claims.

View original content:https://www.prnewswire.com/news-releases/bioedge-research-labs-advances-transparency-in-research-compound-documentation-302874401.html

SOURCE BioEdge Research Labs

Continue Reading

Trending